NCT00070499 2026-03-18
Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
52 trialsNCT04971226 2026-03-10
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Phase 3 Active not recruiting
NCT03654768 2025-12-18
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
SWOG Cancer Research Network
Phase 2 Active not recruiting
NCT03578367 2025-11-10
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Novartis
Phase 2 Completed
NCT00015847 2025-08-22
Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00476190 2025-06-12
ALL Adult Consortium Trial: Adult ALL Trial
Dana-Farber Cancer Institute
Phase 2 Completed
NCT05286528 2023-10-27
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
Pfizer
Completed
NCT01593254 2023-06-22
DASCERN
Bristol-Myers Squibb
Phase 2 Completed
NCT01005914 2023-01-06
Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT01319981 2022-09-27
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03023046 2022-07-13
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
University of Washington
Phase 2 Completed
NCT04006847 2022-07-01
Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Milton S. Hershey Medical Center
Phase 1/2 Terminated
NCT00061945 2022-05-03
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00210119 2021-11-08
AFR22
Institut Bergonié
Phase 2 Terminated
NCT00171223 2021-07-22
An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha
Novartis
Phase 2 Completed
NCT00171249 2021-07-22
An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia
Novartis
Phase 2 Completed
NCT00171158 2021-06-25
An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis
Novartis
Phase 2 Completed
NCT02130557 2021-05-18
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Pfizer
Phase 3 Completed
NCT01827930 2020-12-31
MIM
Institut Bergonié
Phase 3 Terminated
NCT00137111 2020-09-11
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 3 Completed
NCT00509093 2020-03-17
Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00036738 2020-01-29
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT02272777 2019-08-19
A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
Novartis
Phase 3 Completed
NCT00458848 2019-02-15
LAL0904
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT00574873 2019-01-08
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
Pfizer
Phase 3 Completed
NCT02709083 2018-11-02
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
Emory University
Phase 2 Terminated
NCT00038649 2018-10-09
Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00415857 2018-08-21
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00882206 2017-12-28
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT01312818 2017-12-28
Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00702403 2017-08-10
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT01383447 2017-08-08
Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00973752 2017-03-30
Treatment of Older Adults With Acute Lymphoblastic Leukemia
Massachusetts General Hospital
Phase 2 Completed
NCT00481247 2017-02-15
DASISION
Bristol-Myers Squibb
Phase 3 Completed
NCT00760877 2016-11-08
Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)
Novartis
Phase 3 Completed
NCT01275196 2016-04-08
Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients
Novartis
Phase 3 Completed
NCT00982488 2016-01-22
START rollover
Bristol-Myers Squibb
Phase 2 Completed
NCT00022490 2016-01-07
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00802841 2015-11-16
LASOR
Novartis
Phase 3 Completed
NCT00038610 2015-09-18
Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01795716 2015-05-19
Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT00114959 2015-01-15
Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Terminated
NCT01650805 2014-11-17
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Ariad Pharmaceuticals
Phase 3 Terminated
NCT00415909 2014-06-30
TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00320190 2013-10-30
Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib
Bristol-Myers Squibb
Phase 2 Terminated
NCT00333840 2013-10-14
Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Novartis
Phase 3 Completed
NCT00267085 2012-08-07
Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00499889 2012-04-23
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00124748 2012-02-03
TOPS
Novartis
Phase 3 Terminated
NCT00519090 2011-11-07
ENEST
Novartis
Phase 3 Terminated